Skip to main content

Table 3 12-month, seasonal and monthly adherence

From: Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study

 

n

mean ± sd

median

min-max

12 month adherence to Rebif® - Rebismart® (Per Protocol Set)

46

98.32 ± 2.628

99.09

90.30–100

Study adherence to Rebif® - Rebismart® (Full Analysis Set)

62

97.93 ± 5.704

100

90.30–100

Seasonal adherence

 Jan-Mar

61

98.02 ± 6.879

100

57.97–100

 Apr-Jun

57

98.36 ± 5.678

100

60.94–100

 Jul-Sep

55

98.58 ± 3.276

100

81.63–100

 Oct-Dec

56

97.91 ± 6.837

100

52.0–100

Monthly adherence

 Jan

60

97.54 ± 10.409

100

33.33–100

 Feb

60

97.56 ± 8.513

100

54.55–100

 March

59

98.34 ± 7.192

100

54.17–100

 April

57

98.60 ± 6.826

100

50.00–100

 May

57

98.67 ± 6.795

100

52.00–100

 June

53

98.21 ± 5.560

100

65.00–100

 July

52

98.45 ± 5.777

100

60.87–100

 August

49

98.873 ± 2.935

100

86.67–100

 September

52

98.46 ± 4.073

100

81.25–100

 October

53

99.01 ± 2.963

100

86.67–100

 November

52

97.933 ± 6.282

100

68.42–100

 December

59

98.14 ± 6.721

100

52.00–100

  1. Annual adherence: 100 × (total no of injections in 12 months) / expected no of infections in the respective months
  2. Seasonal adherence: 100 × (total no of injections in a 3 month-period) / expected no of infections during the same period
  3. Monthly adherence: 100 × (total no of injections in specific month) / expected no of infections